Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

220,321-220,350 of 319,975

filter-aware
33
The slide outlines a sequential clinical trial process.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
34
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
35
The slide highlights the team's pedigree by listing past company affiliations for each executive and providing a collective logo grid at the bottom.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Team1 hit
36
The slide uses a timeline framework to map patent coverage and exclusivity periods across two main product categories.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
37
The slide provides a snapshot of the company's financial health as of late 2023.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a grouped list format to present clinical trial milestones.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
39
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
01
Slide 1
The slide uses a high-quality lifestyle photo to establish an emotional connection to the company's mission.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathway1 hit
02
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathway1 hit
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathway1 hit
04
SAB stands for Scientific Advisory Board.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathway1 hit
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathwayLoop · Logic Chain1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
07
The slide uses a Gantt-style visualization for clinical trial progress.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
10
The chart uses a stacked bar approach to represent US and Europe patient counts per program, with a total sum at the bottom.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
12
The kinome tree is a standard visualization for kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Cost Of Inaction1 hit
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
17
The slide uses a before-after-framing approach to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
18
The slide uses a swimmer plot to visualize individual patient treatment duration and response status.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
20
Swimmer plot showing individual patient treatment duration and response status (NE, PD, PR, SD).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDs and PRs with specific progression delay metrics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
22
The chart displays adverse events occurring in >=10% of patients (n=15).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit